Developer docs
API playgroundTry for free, no card

Search company profiles

Covidien

Full company profile

uuid000fsti

Namestring
Covidien
Websiteurl
covidien.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Covidien was a global medical device company headquartered in Dublin, Ireland, founded in 2007 and formerly listed on the NYSE under ticker COV, with 10,000+ employees. Following its 2015 acquisition by Medtronic, Covidien now operates as a wholly-owned subsidiary and brand within Medtronic's broader medical device portfolio, with its brand page hosted on Medtronic's website. The company was historically built through both organic development and aggressive M&A, completing roughly 19 acquisitions between 2007 and 2014 across neurovascular, vascular, GI endoscopy, bronchoscopy, patient monitoring, and surgical device categories.

Covidien's product portfolio centers on two core categories: surgical sutures (both monofilament sutures and general surgical suture products, where it is named as a key global competitor alongside Ethicon, B. Braun, and others) and respiratory monitoring devices (where Covidien LLC is identified as a key company in a market projected to reach $2.89B by 2030). Its historical franchises also included minimally invasive surgical devices, neurovascular stroke-treatment devices (via the MindFrame acquisition, now within Medtronic Neurovascular), capsule endoscopy (Given Imaging), electromagnetic navigation bronchoscopy (SuperDimension), brain/EEG monitoring (Aspect Medical Systems), and venous disease treatments (VNUS Medical Technologies).

The company's revenue model is B2B medical device sales to healthcare providers and hospitals globally, with horizontal segmentation across surgical supplies and patient monitoring categories. Pricing is not publicly disclosed in the available sources, and post-acquisition Covidien's financials are consolidated within Medtronic's reporting, with no independent cap table or ownership structure. The Covidien brand continues to surface in ongoing product litigation, particularly hernia mesh multidistrict litigation with 2,000+ federal lawsuits pending as of late 2025.

Short descriptiontext

Covidien is a global medical device company, now a wholly-owned Medtronic subsidiary, that manufactures surgical sutures and respiratory monitoring devices for hospitals and healthcare providers worldwide.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
medical devices, surgical sutures, respiratory monitoring, minimally invasive surgery, neurovascular devices
Industry1 code
1Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
CodeCRADAMAKPrimaryYes
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Medical Devices
Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Covidien manufactures and sells medical devices for healthcare providers and hospitals, with a portfolio that includes monofilament and general surgical sutures and respiratory monitoring devices. The company is positioned as a key competitor in the global surgical sutures market (projected at $13.61 billion in 2025) and the respiratory monitoring devices market (projected to reach $2.89 billion by 2030). Following its 2015 acquisition by Medtronic, Covidien operates as an integrated brand within Medtronic's medical device portfolio.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Covidien, now part of Medtronic, operates as a medical device company offering surgical sutures (both monofilament and general surgical suture products) and respiratory monitoring devices. The company is positioned as a key competitor in multiple medical device market segments including the surgical sutures market and respiratory monitoring devices market. Product portfolio includes monofilament sutures for surgical applications and respiratory monitoring equipment, competing alongside other major medical device manufacturers such as Ethicon, Medtronic, B. Braun, and others.

Product and service3 records
1Covidien Monofilament Sutures
CategorySurgical Sutures
Description

Monofilament sutures manufactured by Covidien for surgical applications including tissue closure in surgical procedures, used by healthcare providers and hospitals.

2Covidien Surgical Sutures
CategorySurgical Sutures
Description

General surgical sutures product line sold by Covidien for use in surgical procedures by healthcare providers and hospitals.

3Covidien Respiratory Monitoring Devices
CategoryPatient Monitoring Devices
Description

Respiratory monitoring devices manufactured by Covidien for clinical patient monitoring in healthcare settings, serving healthcare providers and hospitals.

Partnership1 partner
1MindFrame
Strategic tierCoreTypeTechnology or Integration
Description

Covidien acquired MindFrame (a neurovascular and stroke treatment device company) as part of its expansion into neurovascular medical devices. MindFrame is now part of Medtronic Neurovascular.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A19 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Covidien

Medical Devicescovidien.com

Covidien is a global medical device company, now a wholly-owned Medtronic subsidiary, that manufactures surgical sutures and respiratory monitoring devices for hospitals and healthcare providers worldwide.

What Covidien does

Covidien was a global medical device company headquartered in Dublin, Ireland, founded in 2007 and formerly listed on the NYSE under ticker COV, with 10,000+ employees. Following its 2015 acquisition by Medtronic, Covidien now operates as a wholly-owned subsidiary and brand within Medtronic's broader medical device portfolio, with its brand page hosted on Medtronic's website. The company was historically built through both organic development and aggressive M&A, completing roughly 19 acquisitions between 2007 and 2014 across neurovascular, vascular, GI endoscopy, bronchoscopy, patient monitoring, and surgical device categories.

Covidien's product portfolio centers on two core categories: surgical sutures (both monofilament sutures and general surgical suture products, where it is named as a key global competitor alongside Ethicon, B. Braun, and others) and respiratory monitoring devices (where Covidien LLC is identified as a key company in a market projected to reach $2.89B by 2030). Its historical franchises also included minimally invasive surgical devices, neurovascular stroke-treatment devices (via the MindFrame acquisition, now within Medtronic Neurovascular), capsule endoscopy (Given Imaging), electromagnetic navigation bronchoscopy (SuperDimension), brain/EEG monitoring (Aspect Medical Systems), and venous disease treatments (VNUS Medical Technologies).

The company's revenue model is B2B medical device sales to healthcare providers and hospitals globally, with horizontal segmentation across surgical supplies and patient monitoring categories. Pricing is not publicly disclosed in the available sources, and post-acquisition Covidien's financials are consolidated within Medtronic's reporting, with no independent cap table or ownership structure. The Covidien brand continues to surface in ongoing product litigation, particularly hernia mesh multidistrict litigation with 2,000+ federal lawsuits pending as of late 2025.

Covidien firmographics

Firmographics
Name
Covidien
Website
https://covidien.com
Company type
Private
Founded year
2007
Operating status
Acquired
Headcount range
5,001–10,000 employees
Short description
Covidien is a global medical device company, now a wholly-owned Medtronic subsidiary, that manufactures surgical sutures and respiratory monitoring devices for hospitals and healthcare providers worldwide.
Ownership category
akta.pro rank

Covidien industry classification

Industry
Product category
Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro primary industry
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

  • Medical devices
  • Surgical sutures
  • Respiratory monitoring
  • Minimally invasive surgery
  • Neurovascular devices

Where Covidien is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Markets served

Covidien business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Others

Covidien product offering

Product offering

Core offering

Covidien manufactures and sells medical devices for healthcare providers and hospitals, with a portfolio that includes monofilament and general surgical sutures and respiratory monitoring devices. The company is positioned as a key competitor in the global surgical sutures market (projected at $13.61 billion in 2025) and the respiratory monitoring devices market (projected to reach $2.89 billion by 2030). Following its 2015 acquisition by Medtronic, Covidien operates as an integrated brand within Medtronic's medical device portfolio.

Product overview

Covidien, now part of Medtronic, operates as a medical device company offering surgical sutures (both monofilament and general surgical suture products) and respiratory monitoring devices. The company is positioned as a key competitor in multiple medical device market segments including the surgical sutures market and respiratory monitoring devices market. Product portfolio includes monofilament sutures for surgical applications and respiratory monitoring equipment, competing alongside other major medical device manufacturers such as Ethicon, Medtronic, B. Braun, and others.

Differentiator

Problem solved

Functional benefit

Products and services

  • Covidien Monofilament Sutures Monofilament sutures manufactured by Covidien for surgical applications including tissue closure in surgical procedures, used by healthcare providers and hospitals.
  • Covidien Surgical Sutures General surgical sutures product line sold by Covidien for use in surgical procedures by healthcare providers and hospitals.
  • Covidien Respiratory Monitoring Devices Respiratory monitoring devices manufactured by Covidien for clinical patient monitoring in healthcare settings, serving healthcare providers and hospitals.

Companies that use Covidien

Customer profile

Segments1 record

Ideal customer profiles1 record

Covidien technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Covidien partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MindFramecoreTechnology or IntegrationCovidien acquired MindFrame (a neurovascular and stroke treatment device company) as part of its expansion into neurovascular medical devices. MindFrame is now part of Medtronic Neurovascular.

Recent moves6 records

Expansion highlights5 records

Covidien competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights5 records

Customer concentration

Covidien social profiles

Digital presence

Covidien financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Covidien leadership team

Management profile

Number of profiles

Covidien funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Covidien M&A and investment

M&A and investment

M&A19 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Covidien

What does Covidien do?

Covidien manufactures and sells medical devices for healthcare providers and hospitals, with a portfolio that includes monofilament and general surgical sutures and respiratory monitoring devices. The company is positioned as a key competitor in the global surgical sutures market (projected at $13.61 billion in 2025) and the respiratory monitoring devices market (projected to reach $2.89 billion by 2030). Following its 2015 acquisition by Medtronic, Covidien operates as an integrated brand within Medtronic's medical device portfolio.

Is Covidien a public or private company?

Covidien is a private company. It is classified as corporate owned and is currently acquired.

When was Covidien founded?

Covidien was founded in 2007. It employs 5,001 to 10,000 people.

Where is Covidien based?

Covidien is headquartered in Dublin, Ireland, in the Europe region.

Does Covidien have an API?

No public API is recorded for Covidien.

What industry is Covidien in?

Covidien's product category is Medical Devices. Its primary akta.pro industry code is CRADAMAK, Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business Page$88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether TrialA federal jury ordered Medtronic to pay $88 million in compensatory damages to Larry and Tammy Patterson after finding that its Covidien unit's Symbotex hernia mesh caused serious injuries due to inadequate risk warnings. This verdict represents the highest award for compensatory damages in the history of U.S. mesh product litigation and serves as the first bellwether trial out of over 2,400 pending lawsuits. Medtronic has indicated it intends to challenge the verdict through post-trial motions and a potential appeal.Newsfile$88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether TrialA federal jury ordered Medtronic to pay $88 million in damages after finding that its Covidien unit's Symbotex hernia mesh caused serious injuries due to inadequate warnings about the risks. This verdict, awarded to patient Larry Patterson and his wife Tammy, is the highest compensatory damage award in the 15-year history of U.S. mesh products litigation. Medtronic intends to challenge the verdict through post-trial motions and a possible appeal.Yahoo$88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether TrialA federal jury ordered Medtronic to pay $88 million in compensatory damages to Larry and Tammy Patterson after finding that a hernia mesh made by its Covidien unit caused serious injuries due to inadequate risk warnings. This verdict represents the highest compensatory award in U.S. hernia mesh litigation history and resolves the first of over 2,400 lawsuits coordinated under federal multidistrict litigation. Medtronic denied the allegations and indicated it intends to challenge the verdict through post-trial motions and potential appeals.EIN Presswire$88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether TrialA federal jury ordered Medtronic to pay $88 million to Larry and Tammy Patterson after finding Covidien's Symbotex hernia mesh caused serious injuries and failed to warn doctors of risks. The verdict, the highest compensatory award in 15 years of mesh litigation, is the first of over 2,400 lawsuits in the MDL. Medtronic plans to challenge it in post-trial motions and appeal.Insurance JournalJury Says Medtronic Owes $88 Million in First Trial Over Covidien’s Hernia MeshA federal jury in Boston ordered Medtronic to pay $88 million to an Alabama man and his wife in the first bellwether trial among thousands of cases alleging injuries from hernia mesh implants made by its Covidien unit. The jury found that Covidien failed to provide adequate warnings about dangers posed by the Symbotex mesh implanted in Larry Patterson in 2017, which caused a bowel obstruction requiring reconstructive surgery. The verdict is the largest among more than a dozen hernia and transvaginal mesh cases that have gone to trial, with approximately 10,350 plaintiffs still pursuing claims against Medtronic nationally.FinancialContent Business PageLevin Papantonio Client Awarded $88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether TrialA federal jury ordered Medtronic's Covidien unit to pay $88 million to Larry and Tammy Patterson after finding that Covidien's Symbotex hernia mesh caused serious injuries and that physicians were never adequately warned of the product's risks. The jury awarded $77 million to Larry Patterson and $11 million to his wife on her consortium claim, marking the highest compensatory damages award in the 15-year history of U.S. mesh products litigation. This verdict was the first of more than 2,400 federal lawsuits against Covidien to reach a jury as part of multidistrict litigation MDL No. 3029, with hundreds of additional cases still pending.GlobeNewswireLevin Papantonio Client Awarded $88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether TrialA federal jury ordered Medtronic's Covidien unit to pay $88 million to Larry and Tammy Patterson after finding that Covidien's Symbotex hernia mesh caused Larry serious injuries and that physicians were never adequately warned of the product's risks. Patterson, 61, was implanted with the mesh in 2017, and the collagen coating dissolved in approximately seven days—far sooner than the 30 days doctors were told to expect—causing the mesh to adhere to his bowel and requiring surgical removal along with several inches of intestine. This verdict is the highest award for compensatory damages in the 15-year history of U.S. mesh products litigation, and it is the first of more than 2,400 lawsuits against Covidien to reach a jury in federal multidistrict litigation.BioSpaceAqua Medical Names Bob Haggerty CEO to Take on Type 2 DiabetesAqua Medical appointed Bob Haggerty as CEO, effective July 31, 2026, succeeding Lloyd Mencinger. The company treated its first U.S. patient in the PIMA type 2 diabetes pilot study at UNC Health. The study builds on 66 patients treated outside the U.S. with promising 12-month follow-up.GlobeNewswireLevin Papantonio Client Awarded $88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether TrialA federal jury awarded $88 million to Larry Patterson and his wife in a Covidien hernia mesh trial, finding the mesh's protective coating dissolved prematurely and doctors were not warned of risks. The verdict is the highest compensatory award in 15 years of mesh litigation, and it is the first of over 2,400 lawsuits against Covidien.YahooUS jury says Medtronic owes $88 million in first case to go to trial over Covidien's hernia meshA federal jury in Boston found Medtronic's Covidien unit liable for failing to provide adequate warnings about hernia mesh dangers and ordered the company to pay $88 million to Alabama man Larry Patterson and his wife, after Patterson's mesh implant failed in 2017 requiring reconstructive surgery. This case is the first bellwether, or test case, to go to trial among approximately 10,350 plaintiffs nationally pursuing similar claims against Medtronic over hernia mesh products including Parietex, ProGrip and Symbotex. Medtronic announced it will challenge the verdict through post-trial motions and appeal, despite stating confidence in its hernia mesh products which have been used in millions of patients over two decades.